Hepatitis Antibody Detection Kit Using Lymphocyte Activators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hepatitis C virus (HCV) diagnostic assays face challenges including a long seronegative window period, high false positive rates, and inability to differentiate between chronic and cleared infections, which hinder early detection and accurate diagnosis.
Innovation Solution
A method involving the use of an activator to stimulate hepatitis virus-specific antibody production in a tissue sample by incubating it with hepatitis virus-primed lymphocytes or memory cells, allowing for the formation and detection of antigen-antibody immune complexes, thereby enhancing early detection and differentiation between chronic and cleared infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If current HCV antibody tests are used, then the diagnostic process is simple, but the seronegative window period is long (several months)
Solution Approach 1:
The patent applies preliminary action by stimulating lymphocytes in advance with HCV antigens and mitogens before antibody detection. This pre-stimulation activates memory B cells and induces antibody production ahead of time, allowing detection during the seronegative window period when natural antibodies have not yet appeared in sufficient quantities.
Solution Approach 2:
The patent introduces mitogens (such as phytohemagglutinin or pokeweed mitogen) as intermediary substances that mediate between the HCV antigen and the B cells. These mitogens non-specifically activate lymphocytes, which then become capable of producing HCV-specific antibodies when exposed to the antigen, bridging the gap during the window period.
2Ease of operation
If current HCV antibody assays are used, then the testing procedure is straightforward, but false positive rates are high and variable
Solution Approach 1:
The patent applies local quality by making the immune response highly specific to HCV through dual stimulation: first with HCV-specific antigens to prime antigen-specific B cells, then with mitogens to activate those primed cells. This localized specificity ensures that only HCV-specific antibodies are produced and detected, eliminating cross-reactivity with other viruses that causes false positives.
Solution Approach 2:
The preliminary exposure to HCV antigen before mitogen stimulation ensures that only B cells with HCV-specific receptors are activated. This preliminary action creates a selective memory effect where the subsequent mitogen-induced antibody production is highly specific to HCV, reducing false positives from non-specific immune activation.
3Ease of operation
If routine antibody testing in serum/plasma is performed, then the test is simple to conduct, but it cannot differentiate between current/chronic infection and cleared/resolved infection
Solution Approach 1:
The patent applies dynamics by measuring the rate and magnitude of new antibody production rather than just the static presence of antibodies. By stimulating lymphocytes and measuring the dynamic response (how much antibody is produced and how quickly), the test can distinguish between active infections (high dynamic response) and cleared infections (low or no dynamic response despite presence of antibodies).
Solution Approach 2:
The preliminary stimulation with HCV antigen creates a controlled immune activation that reveals the functional status of the immune system. In chronic infection, the immune system remains responsive and produces antibodies vigorously. In cleared infection, the response is diminished or absent, providing information about current versus past infection status.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces false positive rates, shortens the window period for detection, and accurately differentiates between chronic and cleared infections, improving diagnostic sensitivity and specificity.
Implementation Method 1
exposing the resultant culture of step a) to a hepatitis virus antigen, thereby allowing an antigen-antibody immune complex to form
Data Source
AI summary
The present invention relates to an improved method for detecting antibodies to a hepatitis virus in a tissue sample from individuals, which can reliably detect antibodies in recently infected individuals and which provides much lower false positive results in individuals that have cleared their hepatitis infections. More particularly, the present invention relates to an improved method and kit which utilizes an activator of (i) hepatitis virus-primed lymphocytes, (ii) memory cells specific for said hepatitis virus, (iii) hepatitis virus-specific antibody production, or (iv) a combination thereof in a tissue sample to stimulate the production of antibodies from newly primed B cells, if present.